Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12623001278628
Ethics application status
Approved
Date submitted
16/10/2023
Date registered
7/12/2023
Date last updated
3/04/2024
Date data sharing statement initially provided
7/12/2023
Type of registration
Prospectively registered
Titles & IDs
Public title
Knee Injection Study at St George Hospital (KISS) for the Treatment of Knee Osteoarthritis
Query!
Scientific title
A Double Blinded Three Arm Randomized Controlled Trial of Placebo, Intraarticular Corticosteroid Injection and Genicular Nerve Block for the Treatment of Symptomatic Knee Osteoarthritis
Query!
Secondary ID [1]
310794
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
KISS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
osteoarthritis
331774
0
Query!
Condition category
Condition code
Musculoskeletal
328515
328515
0
0
Query!
Osteoarthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
All interventions are once-off only
Arm 1: Genicular nerve block
o Ultrasound used to localise superolateral genicular nerve (SLGN), superomedial genicular nerve (SMGN), and inferomedial genicular nerve (IMGN)
o Subcutaneous injection of a total of 1ml of 1% lignocaine at three needle entry points for comfort
o Continuous 22-gauge needle visualization to the nerve bundle using a long-axis approach to guide perineural injections of 5.7 mg celestone chronodose (1 ml) and 0.5% bupivacaine (3 ml) at three sites.
o Introduction of 3ml of normal saline into the intraarticular space of the knee joint under direct visualisation
Arm 2: Intraarticular steroid injection:
o Visualisation of the knee joint with bedside ultrasound
o Subcutaneous injection of a total of 1ml of 1% lignocaine at three points for comfort and sham, one of which is the entry point for intraarticular injection, the other two being sham injections
o Introduction of 80mg of methyl-prednisone (2ml) admixed with 1ml of 1% lignocaine to make 3mls into the intraarticular space of the knee joint under direct visualisation
Query!
Intervention code [1]
327207
0
Treatment: Drugs
Query!
Comparator / control treatment
Arm 3: Placebo
o Visualisation of the knee joint with bedside ultrasound
o Subcutaneous injection of a total of 1ml of 1% lignocaine at three points for comfort and sham
o Introduction of 3ml of normal saline into the intraarticular space under direct visualisation
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
336340
0
Pain
Query!
Assessment method [1]
336340
0
Visual analogue score
Query!
Timepoint [1]
336340
0
Week 4 post treatment
Query!
Secondary outcome [1]
427911
0
Pain
Query!
Assessment method [1]
427911
0
Visual analogue score
Query!
Timepoint [1]
427911
0
Weeks 0, 2, 8, 12 post treatment
Query!
Secondary outcome [2]
427912
0
Western Ontario and McMasters Universities Osteoarthritis Index
Query!
Assessment method [2]
427912
0
Questionnaire
Query!
Timepoint [2]
427912
0
Weeks 0, 2, 8, 12 post treatment
Query!
Secondary outcome [3]
427913
0
Safety
Query!
Assessment method [3]
427913
0
Tolerability and Safety Questionnaire
Not designed specifically for this study
(The development of the Tolerability and Safety Index (TASI): a summary single score measure of the ascertainment and reporting of tolerability and safety for indirect trial comparisons, meta-analysisof clinical trials and the evaluation of risk/benefit.for clinical and economic modeling. Lassere M, Johnson K, Finteln S, Rappo J, Balasingam D, Day R, Tugwell P, Anderson J)
Query!
Timepoint [3]
427913
0
Weeks 0, 2, 8, 12 post treatment
Query!
Secondary outcome [4]
429325
0
Intermittent and Constant Osteoarthritis Pain
Query!
Assessment method [4]
429325
0
Questionnaire
Query!
Timepoint [4]
429325
0
Weeks 0, 2, 8, 12 post treatment
Query!
Secondary outcome [5]
429326
0
Global Perceived Effect Scale
Query!
Assessment method [5]
429326
0
Questionnaire
Query!
Timepoint [5]
429326
0
Weeks 0, 2, 8, 12 post treatment
Query!
Eligibility
Key inclusion criteria
• Age >= 18 years
• Able to consent
• Has readily accessible XRs of the knees of less than 12 months duration
• Knee OA as defined by ACR classification criteria
• Chronicity of pain as defined by 4 or more on VAS (1-10) on most days for at least 3 months
• Kellgren-Lawrence score of II or III
• Intraarticular steroid injection to the knee naive
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
• Inflammatory arthritis
• Allergy to intervention compounds
• Pregnancy
• Cognitive impairment or short term memory loss
• Planned orthopaedic surgery within 6 months
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by computer
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer sequence stratified random allocation
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
The sample size with 80% power and alpha of 0.05 to detect a 32mm difference in the VAS (based on previous studies), is36 subjects per arm. In our RCT the control arm is shared between the two interventions / comparisons, and in order to reduce the type 1 error, an alpha is 0.0375 increases the sample size per arm to 39 subjects. With a 10% dropout rate, 44 subjects per arm are needed for a total sample size of 132.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/06/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
1/10/2026
Query!
Actual
Query!
Date of last data collection
Anticipated
1/05/2027
Query!
Actual
Query!
Sample size
Target
132
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
25741
0
St George Hospital - Kogarah
Query!
Recruitment postcode(s) [1]
41565
0
2217 - Kogarah
Query!
Funding & Sponsors
Funding source category [1]
315033
0
Hospital
Query!
Name [1]
315033
0
Department of Rheumatology St George Hospital
Query!
Address [1]
315033
0
St George Hospital, Kensington Street, Kogarah, NSW 2217
Query!
Country [1]
315033
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
St George Hospital
Query!
Address
St George Hospital, Kensington Street, Kogarah, NSW 2217
Query!
Country
Australia
Query!
Secondary sponsor category [1]
317054
0
None
Query!
Name [1]
317054
0
Query!
Address [1]
317054
0
Query!
Country [1]
317054
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
313994
0
South Eastern Sydney Local Health District HREC
Query!
Ethics committee address [1]
313994
0
St George Hospital, Kensington Road, Kogarah NSW 2217
Query!
Ethics committee country [1]
313994
0
Australia
Query!
Date submitted for ethics approval [1]
313994
0
15/01/2024
Query!
Approval date [1]
313994
0
01/03/2024
Query!
Ethics approval number [1]
313994
0
2023/ETH02313
Query!
Summary
Brief summary
There is currently no disease-modifying agents available for knee osteoarthritis and treatment focuses on relief of symptoms such as pain and stiffness. There is limited placebo controlled randomised clinical trial data for a number of procedures to improve symptoms of knee osteoarthritis to improve function. These include steroid injections into the joint and blocking the nerves that supply the joint. These interventions have not been adequately studied against placebo. This study will look at comparing the effectiveness and safety profile of these two technqiues agents against a shared placebo group to see if they are effective. A further exploratory outcome is how well these interventions compare against each other if they prove effective against placebo.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
130054
0
Dr Alwin Lian
Query!
Address
130054
0
St George Hospital, Kensington Street, Kogarah 2217 NSW
Query!
Country
130054
0
Australia
Query!
Phone
130054
0
+61291132513
Query!
Fax
130054
0
Query!
Email
130054
0
[email protected]
Query!
Contact person for public queries
Name
130055
0
Alwin Lian
Query!
Address
130055
0
St George Hospital, Kensington Street, Kogarah 2217 NSW
Query!
Country
130055
0
Australia
Query!
Phone
130055
0
+61291132513
Query!
Fax
130055
0
Query!
Email
130055
0
[email protected]
Query!
Contact person for scientific queries
Name
130056
0
Alwin Lian
Query!
Address
130056
0
St George Hospital, Kensington Street, Kogarah 2217 NSW
Query!
Country
130056
0
Australia
Query!
Phone
130056
0
+61425876842
Query!
Fax
130056
0
Query!
Email
130056
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
all of the individual participant data collected during the trial, after de-identification
Query!
When will data be available (start and end dates)?
End of recruitment for 10 years
Query!
Available to whom?
researchers who provide a methodologically sound proposal, case-by-case basis at the discretion of Primary Sponsor
Query!
Available for what types of analyses?
meta-analyses
Query!
How or where can data be obtained?
via secure email after approval is granted
[email protected]
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF